22 February, 2017

Michael Clayman, M.D., CEO of Flexion Therapeutics talk about the need for new treatment options for osteoarthritis (OA) and Flexion’s lead investigational product candidate, ZilrettaTM

This morning, Michael Clayman, M.D., CEO of Flexion Therapeutics (Nasdaq: FLXN), appeared live on Fox Business News to talk about the need for new treatment options for osteoarthritis (OA) and Flexion’s lead investigational product candidate, ZilrettaTM (FX006) which is being evaluated as a potential new therapy for OA related knee pain. A link to Mike’s interview can be found below:

http://finance.yahoo.com/video/developing-alternatives-opioids-relieve-pain-130004965.html

Michael Clayman, M.D., CEO of Flexion Therapeutics talk about the need for new treatment options for osteoarthritis (OA) and Flexion’s lead investigational product candidate, ZilrettaTM

HighLife Raises $90+Million to start its US Pivotal Study and accelerate Commercial Expansion in Europe

Before the breakthrough: Sofinnova's decade-long bet on HighLife

Actithera strengthens leadership team and Board as company advances towards clinical development

Bionyra Pharma announces first healthy volunteers dosed in Phase 1 study of BYN-001, a long-acting IL-25 antibody for atopic dermatitis

NodThera changes name to Rezera Inc. and announces Ruvonoflast Phase 3 development program

ProQR announces first participant dosed in Phase 1 study of AX-0811